In response to client requirements, global service provider Almac’s expansion of their API manufacturing facility at its European headquarters in Craigavon, U.K. is near completion, and will be operational by the end of the year.
The upgrade includes installation of two 1,000L reactors and state-of-the-art pressure filter dryer, which allows production of GMP Active Pharmaceutical Ingredients (API) up to 150kg batch size.
“Almac’s investment has further demonstrated our goal of being the outsourcing partner of choice through all stages of clinical development,” said Denis Geffroy, vice president of business development, Almac. “We are delighted to have the scale to share the manufacturing journey with our clients from preclinical phase to full commercialization.”
Clients can also leverage Almac’s API and drug product integrated offering where API manufacture and finished drug production is carried out on the same site, ensuring reduction in costs and timelines whilst maintaining scientific continuity. Almac’s advantage of hosting all facilities on one site have led to the successful technology transfer of small molecule and peptide projects from lab development to large scale manufacture.